University of Mississippi
Also known as: Babbette Lamarca | Batson Children's Hospital, University of Mississippi Medical Center | Department of Emergency Medicine, University of Mississippi School of Medicine | Gailen D. Marshall Jr., MD PhD | Joshua Sharp | Mississippi College | Principal Scientist, National Center for Natural Products Research | Suvankar Majumdar | University of Mississippi and Carolinas Medical Center, Department of Emergency Medicine | University of Mississippi Cancer Clinic | University of Mississippi Medical Center | University of Mississippi Medical Center (Adult) | University of Mississippi Medical Center, Jackson, USA | University of Mississippi Medical Center (Pediatric) | University of Mississippi Medical Center, School of Physical Therapy | University of Mississippi Medican Center | University of Mississippi, Oxford | University of Mississsippi
Highest phase reached
Phase 4
First clinical trial
Oct 1, 1974Last known activity
Mar 1, 2024
Timeline
1840s
- Jun 1, 1848
University of Mississippi— Founded
Drugs by trial phase (86 distinct, 68 trials)
Phase 4 (4 own, 0 via acquisition)
Phase 3 (23 own, 0 via acquisition)
Phase 2 (13 own, 0 via acquisition)
Phase 1 (18 own, 0 via acquisition)
Other trials (28 own, 0 via acquisition)
Indications
Studied for
- Acute Chest Syndrome
- Anemia
- Anemia, Sickle Cell
- Asthma
- Cardiovascular Diseases
- Catatonia
- Chemotherapy-Induced Febrile Neutropenia
- Complex Regional Pain Syndromes
- Coronary Disease
- Diabetes Mellitus
- Diabetes Mellitus, Type 2
- Embolism
- Endocardial Cushion Defects
- Epilepsy
- Febrile Neutropenia
- Fistula
- Glucosephosphate Dehydrogenase Deficiency
- Heart Diseases
- Heart Septal Defects
- Heart Septal Defects, Atrial
- Heart Septal Defects, Ventricular
- Hematologic Diseases
- Hemoglobinopathies
- Hemorrhage
- Hyperlipidemias
- Hyperlipoproteinemias
- Hypertension
- Hypertension, Renovascular
- Hypospadias
- Hypoxia
- Infarction
- Ischemia
- Kidney Diseases
- Lung Neoplasms
- Malaria
- Multiple Myeloma
- Myocardial Infarction
- Myocardial Ischemia
- Neoplasms
- Neoplasms, Plasma Cell
- Neutropenia
- Nodding Syndrome
- Pneumonia
- Postoperative Nausea and Vomiting
- Pre-Eclampsia
- Pulmonary Embolism
- Reflex Sympathetic Dystrophy
- Renal Artery Obstruction
- Renal Insufficiency, Chronic
- Sciatica
- Shock, Septic
- Subarachnoid Hemorrhage
- Suicidal Ideation
- Syndrome
- Vascular Diseases
- Vasospasm, Intracranial
- Vomiting
Recent trials (50)
- NCT03676049Lead sponsorN/A—
- NCT06274021OfficialEarly Phase 1Mar 1, 2024
- NCT06274021Lead sponsorEarly Phase 1Mar 1, 2024
- NCT06274021Sponsor investigatorEarly Phase 1Mar 1, 2024
- NCT05687058Lead sponsorPhase 1/Phase 2Oct 1, 2023
- NCT05687058Overall official - principal investigatorPhase 1/Phase 2Oct 1, 2023
- NCT05524532Lead sponsorN/ASep 28, 2022
- NCT05524532Overall official - principal investigatorN/ASep 28, 2022
- NCT05447078Overall official - principal investigatorN/AJul 1, 2022
- NCT05447078Lead sponsorN/AJul 1, 2022
- NCT05040776Study directorPhase 2Dec 31, 2021
- NCT04770155Reponsible party - principal investigatorEarly Phase 1May 27, 2021
- NCT04770155Lead sponsorEarly Phase 1May 27, 2021
- NCT04770155Overall official - principal investigatorEarly Phase 1May 27, 2021
- NCT05076955Overall official - principal investigatorEarly Phase 1Mar 31, 2021
Details
- Founded
- Oxford, MS, US Jun 1, 1848
- Last known activity
- Mar 1, 2024